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Interactions with cervix epithelial and monocytic cells and influence on cytokines and 
secretory leukocyte protease inhibitor, SLPI 
Louise Strömbeck 
Department of Infectious Medicine, Gothenburg University
Abstract
  Lactobacillus is the predominant species of the vaginal microbiota in women of childbearing age. 
Lactobacilli are thought to contribute to the local immune defence by producing a variety of 
antimicrobial substances and, thereby, attenuate growth of other opportunistic bacteria. A disturbed 
vaginal microbiota, with loss of lactobacilli and an overgrowth of other anaerobic bacteria such as 
occurs in cases of bacterial vaginosis (BV), increases susceptibility to sexually transmitted infections, 
risk of ascending infections to the upper genital tract and postoperative infections, which can pose a 
threat to pregnancy and cause preterm birth (PTB).  
  Antimicrobial polypeptides (AMPs) are important molecules of the mucosal innate immune defence. 
Secretory leukocyte protease inhibitor (SLPI) is a multifunctional AMP that is present at high 
concentrations in the healthy female genital tract. Thus, the presence of a healthy microbiota, such as 
lactobacilli, and the surveillance by the mucosal innate immune system are suggested to be important 
factors for the homeostasis of the lower genital tract. 
  Our aim was to analyse the occurence of virulence features in the opportunistic Gram-negative 
bacterium Prevotella bivia, commonly found in BV, associated with upper genital tract infection and 
PTB, and to investigate whether vaginal lactobacilli interact with the host innate immune defence, by 
affecting the regulation of SLPI and pro-inflammatory cytokine responses in host cells. 
  Studies of the anaerobic bacterium P.bivia showed that one out of five strains tested had a high 
capacity to invade HeLa cells. The lack of adhesion structures on P.bivia, as well as a similar capacity 
of different strains to adhere to HeLa cells, suggested that P.bivia are endowed with some other factor 
important for the intracellular invasion. Only the most invasive strain of P.bivia gave rise to a weak 
IL-6 and IL-8 response. Thus, a high invasion capacity together with a low pro-inflammatory cytokine 
response in certain strains of P.bivia are suggested to be virulence factors in establishing a subclinical 
upper genital tract infection. 
  Analysis of isolates of the four most frequent vaginal Lactobacillus spp. (L.crispatus, L.iners,
L.gasseri and L.jensenii), regarding the capacity to influence the secretion and expression of SLPI in 
monocytic- (THP-1) and cervix epithelial- (HeLa) cells, showed that L.iners could up-regulate the 
constitutive secretion of SLPI. However, high concentrations of L.iners down-regulated the SLPI 
secretion in both cell types. The largest difference between the four lactobacilli species in their 
regulation of SLPI was obtained between L.iners and L.crispatus. At the concentrations tested, 
L.crispatus gave rise to a strong reduction of SLPI in both cell types. A negative correlation was found 
between SLPI protein and mRNA expression levels in HeLa cells, but not in THP-1 cells. In both cell 
types, synergy effects in the pro-inflammatory cytokine response were obtained by co-incubation of 
lactobacilli with E.coli. Positive synergy effects were obtained for the IL-8 and TNF-? production in 
THP-1 cells and for IL-6 and IL-8 in HeLa cells. Negative synergy effects were obtained for IL-6 and 
IL-18 in THP-1 cells. Moreover, negative correlations were obtained between the cytokines and SLPI 
levels. Analysing the effects of the addition of recombinant SLPI to HeLa cells prior to the exposure to
E.coli showed a significant reduction of the IL-6 and IL-8 responses in the cells.  
 The results indicated that vaginal lactobacilli can contribute to the regulation of SLPI and pro-
inflammatory cytokine responses in host cells. However, our data also suggested that a dominating 
Lactobacillus spp., such as L.iners or L.crispatus, may influence the mucosal innate immune defense 
in different ways. Moreover, the regulatory effect on the SLPI secretion was inversely associated with 
the capacity of the bacteria to evoke pro-inflammatory cytokines in the host cells.  
Key words: Prevotella bivia, bacterial vaginosis (BV), invasion, Lactobacillus, secretory leukocyte 
protease inhibitor (SLPI), cytokines,THP-1 cells, HeLa cells. 
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ABBREVATIONS
AMPs          antimicrobial peptides/proteins  
BV               bacterial vaginosis
FGT             female genital tract 
IL                 interleukin
LPS              lipopolysaccharide
LTA             lipoteichoic acid
MAMP microbe-associated molecular patterns  
NFκB           nuclear factor kappa B 
PRRs            pattern recognition receptors
PTB preterm birth  
SLPI            secretory leukocyte protease inhibitor
STDs            sexually transmitted diseases  
TLRs toll like receptors
TNF-? tumor necrosis factor – ?
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1. INTRODUCTION 
1.1 The female genital tract
The female genital tract (FGT) (fig.1) is 
composed of a sequence of cavities, the 
vagina, endocervix, uterus and Fallopian 
tubes, which allow for passage in both 
directions. The upper genital tract 
comprising the endocervix, uterus and 
Fallopian tubes, is well protected from 
vaginal microorganisms unless the cervix 
becomes infected. The cervical opening is  
normally filled with a mucus plug that is 
effective in preventing the entry of 
microorganisms into the uterus. However, 
this plug is not always impermeable. In the 
middle of the menstrual cycle, the cervical 
mucus changes in viscosity to allow sperm 
to enter the uterus. Despite the apparent 
vulnerability of the female upper genital 
tract, infections of this area do not occur 
frequently.
Endocervix
Fallopian tubes
Ovary
Vagina 
Uterus
Ectocervix
Cervix
Fig 1. Female genital tract (FGT). Infections in FGT may target the 
cervix and ascend to the uterus and Fallopian tubes. The most common 
infection of the vagina is bacterial vaginosis (BV) and yeast infections. 
1.2  Infections of the FGT
1.2.1. Sexually transmitted diseases,
          STDs
Sexually transmitted diseases (STDs) are 
caused by pathogens that are commonly 
transmitted through sexual contact. They 
make up a major portion of infectious 
diseases and are a significant public-health 
and financial burden on society worldwide. 
Examples of STDs are human papilloma-
virus (HPV) and Chlamydia trachomatis, 
which are extremely prevalent STDs, while 
human immunodeficiency virus (HIV) is 
associated with a high rate of mortality. 
The major complication associated with 
HPV (type 16 and 18) infection is cervical 
cancer [1], and with C.trachomatis there is 
an increased risk of pelvic inflammatory 
disease (PID), ectopic pregnancy, preterm 
birth (PTB), and infertility.
Despite a high prevalence of STDs, 
vaccines against only two viral STDs are 
available, HPV (cancer and wart-inducing 
HPV types) and Hepatitis B virus.
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C. trachomatis and N. gonorrhoeae can 
overcome the immune defence in the 
cervix. Once such bacteria have infected 
the cervix, the chance of an ascending 
infection increases. Both pathogens are
able to grow and multiply in the cervix, 
uterus, and fallopian tubes. 
Even though symptoms of chlamydia or 
gonorrhea are usually mild or absent, 
serious complications such as infertility 
can occur silently before it is recognized as 
a problem. Both C. trachomatis and N.
gonorrhoeae are intracellular pathogens. 
This intracellular invasion capacity is 
probably a prerequisite in order to escape 
the hostile luminal milieu of the vagina and 
cervix.
A consequence of gonorrhea and chla-
mydial disease or the viral disease herpes 
is the increased risks for acquisition of 
HIV [2]. It is assumed that the local 
inflammatory responses in the cervix 
induced by the primary STD lead to more 
dense populations of immune cells, which 
are targets of the HIV viruses.  
1.2.2  Bacterial vaginosis, BV
Bacterial vaginosis (BV) is the most 
common cause of vaginal infection in 
women of childbearing age. BV is 
characterised by an imbalance of the 
vaginal microbiota with a marked reduc-
tion of lactobacilli species, an overgrowth 
of a mix of mainly endogenous obligately 
anaerobic bacterial spp., and elevated pH 
in the vagina [3-5]. Women with BV may 
have an abnormal white or grey thin 
vaginal discharge with an unpleasant odor. 
BV may be accompanied by pain, itching, 
or burning [6], although the occurrence of 
BV with no signs or symptoms is estimated 
to account for half of all cases [7]. The 
total number of bacteria associated with 
BV is increased 100-1000 fold compared 
to normal levels. Thus, there is both a 
qualitative and quantitative change of the 
microbiota with BV. The presence of 
anaerobic bacteria gives rise to amines and 
an elevated pH, which further promotes the 
growth of anaerobic bacteria [8]. 
Among the bacterial spp. commonly found 
in BV are Gardenerella vaginalis, Atopo-
bium vaginae, Prevotella spp., Mobiluncus
spp., Mycoplasma hominis and Urea-
plasma spp. [9-11]. However, the list of 
BV-associated bacteria is growing, since 
new species are being revealed, due to the 
use of cultivation independent methods of 
detection.
A virulence property of Prevotella sp. and 
some other species is the secretion of 
hydrolytic enzymes. It has been suggested 
that the capacity to degrade mucins by 
sialidases would facilitate the adhesion of 
bacteria to vaginal host cells and thereby 
colonization of the epithelium [12, 13]. 
Bacterial hydrolytic enzymes may also 
affect other secreted host factors such as 
antibodies and antimicrobial polypeptides/ 
proteins (AMPs) [14, 15].   
In most cases, BV causes no comp-
lications, although it does present some 
serious risks health risks. Several studies 
have shown an association between BV 
and an increased susceptibility to STDs 
such as HIV-1, Herpes simplex virus, 
HPV, N. gonorrhoeae, and C. trachomatis
[16-21].
BV has also been associated with an 
increased risk of endometritis, PID, and 
postoperative infections (hysterectomy, 
legal abortion [22-26]. The cure rate of BV 
by antibiotic treatment is between 60-70 % 
[27].
1.2.3 Ascending infections and preg-
nancy complications
PTB is the major cause of neonatal 
mortality and long term morbidity [28]. 
PTB, defined as birth before 37 weeks of 
gestation, occurs in circa 5-10% of all 
deliveries in developed countries. [29-33]. 
Approximately 50% of all premature births 
are idiopathic (termed “spontaneous 
PTB”). A growing body of evidence 
suggests genital infection and/or 
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inflammation as major causes of spon-
taneous PTB. Infections from organisms 
such as N. gonorrhoeae, C. trachomatis, 
Trichomonas vaginalis, PID and BV have 
been shown to significantly increase the 
risk of PTB [17, 29, 34, 35]. A strong 
association has also been found between 
BV and late spontaneous abortion 
(gestational week 16-24) [36, 37].  Some 
of these infections often occur without 
clinical symptoms. Thus, clinically silent 
upper genital infections and inflammation 
are strongly associated with an increased 
risk of spontaneous PTB [38-40]. Although 
BV is a marker for increased risk of PTB, 
it may not be the actual cause. A possible 
pathogenic mechanism has been suggested 
to be an ascending subclinical infection, 
which can lead to a microbial invasion of 
fetal membranes, bacterial invasion of the 
amniotic cavity and eventually to a fetal 
infection [38, 41, 42]. Several bacterial 
species isolated from the amniotic cavity 
of patients with spontaneous preterm 
labour and intact fetal membranes have 
been shown to be similar to those that are 
commonly found in BV. Among these 
bacterial spp. are Gardnerella vaginalis, 
Prevotella sp. Mycoplasma hominis, 
Ureaplasma sp., and Mobiluncus sp. [9-11,
43]. Prevotella spp., such as P. bivia,
which is associated with preterm birth and 
is one of the most frequent species isolated 
from the amniotic fluid of patients with 
intra-amniotic infection, have been shown 
to increase the rate of PTB twofold in 
women with preterm labor [44-46].  
1.3  Innate immune defence of the 
FGT
The innate immune system of the female 
reproductive tract is an important factor in 
the prevention of ascending genital infec-
tions that can threaten pregnancy and fetal 
development. The mucosa of the lower ge-
nital tract has to selectively support a ha-
bitat for resident commensal microbes and, 
at the same time, inhibit the growth of po-
tential pathogens, whereas the upper geni-
tal tract must remain aseptic.   
The components that constitute the innate 
immune defense of the FGT can be divided 
into; 1) morphological and physical de-
fence features, 2) commensal bacteria 
colonizing the vagina, and 3) membrane-
associated- and soluble factors [47, 48]. 
The innate immune system of the FGT is 
partly under hormonal control. The 
thickness of the endometrium (the lining of 
the uterus) (fig. 1), and its immune system 
change with fluctuating estrogen and 
progesterone levels during the menstrual 
cycle and pregnancy [49-51]. 
1.3.1  Morphological and physical de- 
fence features 
The FGT can be divided into the lower 
genital tract (vagina and ectocervix) lined 
by multilayered nonkeratinized stratified 
squamous epithelium (fig. 2A), and the 
upper genital tract (endocervix, uterus, and 
fallopian tubes) lined by simple columnar 
epithelium (fig.2B). The lower and upper 
genital tract is connected via the cervix, 
which is composed of three different 
anatomical regions; the ectocervix (the 
outer part facing the vaginal lumen), a 
transformation zone (TZ), and the 
endocervix (facing the lumen of the 
cervical canal)(fig 1). The TZ constitutes 
an abrupt junction between the stratified 
squamous epithelium of the ectocervix and 
the columnar epithelium of the endocervix. 
The cervix forms a narrow canal and the 
cervical mucus is highly microbiocidal due 
to its content of a variety of AMPs that are 
active against a broad spectrum of 
microbes [52, 53]. 
Epithelial cells and the mucus layer 
function as a first physical barrier against 
potential pathogens [54]. The mucus
physically protects the mucosa by hind-
ering bacterial attachment and penetration.
Immune cells. Immune cells such as mac-
rophages, dendritic cells (DCs), Langer-
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hans cells, NK-cells, B cells and T cells are 
present throughout the genital tract mucosa 
with the highest concentrations located in 
the cervix (fig.2). Although no distinctive 
lymphoid structures are present in the 
genital tract, lymphoid aggregations 
containing B cells, CD8+/CD4- T cells, 
and macrophages have been reported to 
form in the transformation zone of the cer-
vix. The highest number of macrophages 
and T cells are found in the TZ whereas 
macrophages, DCs, and T cells seem to be 
relatively sparse in the ectocervix and 
vagina. Additionally, numerous neutrophils 
also reside in the TZ. Macrophages, NK 
cells, and T cells are located in the lamina 
propria and as intraepithelial cells in the 
lumenal and glandular epithelium of the 
endocervical mucosa (fig 2B) [48, 55, 56]. 
Epithelial cells. The epithelial cell layer in 
the vagina and ectocervix is continuously 
sloughed off and is thereby also reducing 
the amount of attaching microbes (fig.2A) 
[57]. However, besides being a physical 
barrier for micro-organisms, mucosal 
epithelial cells may actively participate in 
the mucosal immune defence by secreting 
cytokines in response to pathogens [58] 
The cytokine response of the mucosal epit-
helium depends partly on the type of epit-
helial cells and pathogens involved. [59, 
60].  Both invasive and non-invasive 
strains of N.gonorrhoeae induce the pro-
inflammatory cytokines interleukin-6 (IL-
6) and IL-8 in immortalized epithelial cells 
of the human ectocervix, endocervix, and 
vagina [61]. C. trachomatis invasion of a 
cervical cell line (HeLa) has been shown to 
induce the secretion of the pro-inflamma-
tory cytokines IL-1?, IL-6, IL-8, and IL-18 
[62] [63].
1.3.2  Membrane associated factors 
A characteristic feature of innate immunity 
is the ability to recognise structurally con-
served molecules derived from microbes 
and microbe-associated molecular patterns 
(MAMP) via pattern recognition receptors 
(PRRs) on the host cells. PRRs can be in 
either a soluble, membrane-bound or 
cytosolic form and function either at an 
extracellular or intracellular level. 
Examples of PRRs are: CD14 a molecule 
which can be either soluble or bound to 
external membrane [64, 65], the membrane 
bound mannose receptor (MR), dendritic 
cell-associated C-type lectin-1 (dectin-
1)[66], Toll like receptors (TLRs), the 
intracellular NOD-like receptors (NLRs), 
and retinoic-acid-inducible gene (RIG)-like 
helicases (RLHs) [67-70].
TLRs. The TLRs, which are transmem-
brane proteins localized either at the cell 
surface or within phagosomes/endosomes, 
are one of the most extensively invest-
tigated PRRs. Ten different human TLRs 
have been identified, each with a distinct 
MAMP specificity. TLRs are evolution-
narily conserved membrane-bound PRRs 
that recognize a broad spectrum of 
MAMPs including carbohydrates, lipids, 
proteins, and nucleic acids [70]. Examples 
of TLRs and their specific MAMPs ligands 
are displayed in Table 2. Expressions of 
TLRs have been found in various tissues 
and on a variety of cell types such as 
macrophages, DCs, neutrophils, fibro-
blasts, and epithelial cells [68, 71]. The 
distribution of some TLRs in the FGT are 
summarised in Table 3. Notable, TLR 4, 
which binds lipopolysaccharide (LPS) does 
not seem to be expressed in epithelial cells 
of the vagina, ectocervix, or endocervix 
regions of the FGT that are constantly 
exposed to endogenous and exogenous 
microbes. TLR2, which is another 
important receptor for bacteria, is 
expressed in minor amounts in the same 
epithelial cells. In contrast, the 
endometrium expresses both TLR4 and 
TLR2. The co-receptor molecules MD2 
and CD14 are both involved in binding 
bacterial cell wall components. CD14 
enhances the sensitivity towards bacteria 
and bacterial products [72] [73], while
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squamous epithelial cell
Lactobacilli
BV-associated bacteria
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epithelium
Proximal 
lymph node
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Sloughing 
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Lactic acid         low pH 
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Fig 2. The female genital tract (FGT) with magnified vaginal (A) and cervical (B) epithelium. A) a multilayered 
squamous epithelium is lining the vagina and ectocervix. Macrophages, dendritic cells (DCs) and T cells are 
mainly present in the sub-mucosal area, although a sparse distribution of these cells also can be found in the 
epithelium. Epithelial cells are constantly sloughed off from the surface, thereby diminishing the number of 
bacteria attached to the epithelium. Epithelial cells also contain glycogen, which support the growth of 
lactobacilli and the production of lactic acid, which lower the pH in the vagina. B) the lining of the proximal part 
of cervix, the endocervix, consists of a single layered columnar epithelium. Macrophages, T cells, and NK cells 
are present in the epithelium and in the sub-mucosa. However, no dendritic cells appear to be present in the 
endocervix. 
 
 
MD2 is required for a LPS-induced signal 
transduction [74]. 
 
 
1.3.3  Soluble factors  
Mucosal secretion of the vaginal and 
cervical epithelia contain an abundance of 
soluble factors that participate in a local 
non-specific innate immune defence. 
Among the secreted soluble factors are 
components of the complement system, 
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cytokines, chemokines, nitric oxide, 
fibronectin, and AMPs [47, 48, 55, 75].  
Antimicrobial factors. AMPs have a non-
specific anti-microbial activity to a broad 
spectrum of bacteria fungi, and viruses. 
Some AMPs are enzymes (e.g., lysozyme) 
that disrupt essential microbial structures, 
others bind essential nutrients denying 
them to microbes, and some act by 
disrupting microbial or viral membranes 
(defensins) [76-78]. Since most AMPs are 
cationic, they are thought to be attracted to 
anionic components on the surface lipid 
membranes of bacteria, viruses, fungi, and 
protozoa by electrostatic attraction and 
thereby cause cell wall disrupttion and 
lysis [47, 48, 79].  
The mucus of the FGT contains a variety 
of AMPs such as defensins, cathelicidins, 
lactoferrin, lysozyme, calprotectin, elafin, 
and secretory leukocyte protease inhibitor 
(SLPI) [80-83]. 
In women with BV, the levels of AMPs 
and antibacterial activity have been 
reported to be decreased, compared to 
levels in healthy women [84]. 
 
 
 
 
 
 
 
 
 
 
 
 
 
Microbial products     TLR  
(MAMPS): 
Table 2.    Microbial ligands to human TLRs 
 
• Atypical LPS  (gramneg)    
• Peptidoglycan (PG)  (grampos and gramneg)   
• Lipoteichoic acid (LTA)  (grampos)    
• Lipoarabinomannan (LAM)  (Mycobacteria)  TLR2 
• Porins    (Neisseria)    
• Lipoprotein/lipopeptides  (a variety of pathogens) 
 
● Diacyl lipopeptides  (mycoplasma)  TLR6/TLR2 
• Triacyl- lipopeptides   (bacteria and mycobacteria) TLR1/TLR2 
 
• LPS    (gramneg)  TLR4/MD2# 
• LTA, chlamydial LPS, HSP60, viral protein  (gramneg, viruses) TLR4 
 
• Flagellin   (bacteria)  TLR5 
 
• CpG DNA  (bacteria, C.albicans) TLR9* 
 
• Glucans (Zymosan)  (fungi)  Dectin-1/ TLR2  
 
•     ssRNA (viral)   (antiviral compounds) TLR7*, TLR8* 
 
• dsRNA  (viral)  (viruses)  TLR3* 
 
 
# MD2 is a cofactor for LPS induced signal transduction.  
 
 
 
*  intracellular 
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Table 3. PRR expression in epithelial cells isolated from  different  
               locations of the FGT*. 
_________________________________________________________
PRRs Vagina            Ectocervix       Endocervix         Endometrium              
_________________________________________________________
TLR 2                +/-#                    +/-                   +/-                    +/+++ 
TLR 3                +++           +++   +++                      +++ 
TLR 4                   -                      -     -               ++ 
CD14                   + ND                   +/-                      +
_________________________________________________________
* Author’s unpublished results 
+ expression of mRNA 
          - no mRNA expression 
         # individual variation  
         ND not done 
1.3.4  The vaginal microbiota
One of the most important defence 
mechanisms against infections in the FGT 
is the composition of the microbiota that 
colonizes the vagina. Lactobacilli are the 
predominant species of the vaginal micro-
biota in healthy women of childbearing age 
[47, 85, 86]. Glycogen, which is released 
from vaginal epithelial cells, supports the 
growth of lactobacilli. Since the production 
of glycogen is controlled by estrogen a 
dominance of lactobacilli is found in fertile 
women [87].  
Other bacteria such as Streptococcus spp., 
Staphylococcus spp., Gardnerella vagi-
nalis, and Enterococcus faecalis are exam-
ples of bacterial species that occur in low 
concentrations in the FGT microbiota of 
healthy women [3, 88]. The presence of 
Lactobacillus spp. in the vaginal mic-
robiota is associated with a reduced risk of 
BV, ascending genital tract infections, and 
sexually transmitted diseases (STDs) [89-
92].
In 1892 the German obstetrician, Albert 
Döderlein (1860 – 1941), was the first to 
describe a rod shaped Gram-positive 
bacterium in the vagina that, subsequently, 
was named “Döderlein’s bacillus”. 
Lactobacilli which are found primarily in 
the mucus of the vagina are facultative 
anaerobes. These belong to the group of 
lactic acid bacteria, due to their ability to 
produce lactic acid [93].
L.iners, L.crispatus, L.jensenii and L. 
gasseri have been reported to be the most 
predominant Lactobacillus species in the 
vaginal microbiota. Additionally, in the 
majority of women with a Lactobacillus
dominated microbiota, only one species 
appears to dominate [47, 85, 86, 94-97].  
Lactobacilli are thought to prevent the 
growth of non-residential bacteria by 
several mechanisms. The glycogen 
released from vaginal epithelial cells is 
metabolised by lactobacilli into lactic acid, 
which lower the pH of the vaginal fluid to 
pH 3.5 – 5 (fig 1A). A low pH is per-
missive for lactobacilli and other resi-
dential commensal bacteria that can grow 
in an acid environment, but is anti-
microbial against non-resident species [53, 
57, 80]. Additionally, the production of 
antimicrobial substances such as hydrogen 
peroxide (H2O2), bacteriocins, and other 
organic acids by the lactobacilli, together 
with the competition for adhesion sites and 
nutrients are all factors that contribute in 
preventing the growth of other resident and 
non-resident bacterial species (fig 1A) [89, 
98-102].
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2.SPECIFIC BACKGROUND 
2.1 Intracellular invasion 
Adhesion to and invasion of mucosal 
epithelial cells is a strategy for the 
establishment of infection used by several 
bacterial pathogens such as C.  trachomatis 
and  N. gonorrhoeae [103]  [104]. Invasion 
of human oral epithelial cells by anaerobes 
such as Prevotella intermedia, Porphyro-
monas gingivalis, and Actinobacillus 
actinomyc-temcomitans has been suggested 
as a pathogenic mechanism for periodontal 
disease, a chronic polymicrobial infection 
with a slowly progressing inflammation 
and destruction of tissue [105-108].
Micro-organisms present in the lumen of 
the cervix are surrounded by high con-
centrations of AMPs. To survive in such a 
hostile milieu micro-organisms need to be 
covered by a protective surface, degrade 
AMPs by the secretion of proteases, or 
being able to invade epithelial cells [109, 
110]. For example, sialidases produced by 
Prevotella spp. such as P.bivia and some 
other micro-organisms present in the 
microbiota of patients with BV, are likely 
to represent virulence factors that act by 
destroying mucins and proteins, and there-
by enhancing the adherence of bacteria to 
epithelial cells. Adhesion of a pathogenic 
micro-organism to its host is the first stage 
in any infectious disease. 
2.2 Cytokines and chemokines 
Pro-inflammatory cytokines are small 
proteins that function primarily in the 
induction of inflammation. The concept is 
based on the genes coding for the synthesis 
of small mediator molecules that are up-
regulated during inflammation. Examples 
of pro-inflammatory genes are type II 
phospholipase A2, cyclooxygenase-2 and 
inducible NO synthase. These genes codes 
for enzymes that increases the synthesis of 
platelet-activating factor, leukotrienes, 
prostanoids, and nitric oxide (NO) [111]. 
Another feature is enhancement of the 
innate immune responses [112]. NFkB is 
an important transcription factor in non-
lymphoid cells for all the cytokines 
described below. 
IL-1 and TNF-?. Interleukine -1 (IL-1) 
and tumor necrosis factor – ? (TNF-?),
proteins with molecular masses of 15- to 
18-kDa are particularly effective in in-
ducing the expression of pro-inflammatory 
genes and may act in synergy in this pro-
cess. These cytokines initiate a cascade of 
inflammatory mediators by inducing endo-
thelial adhesion molecules in endothelial 
cells. This event is essential for the ad-
hesion of leukocytes to the endothelial 
surface, which is a first step in the 
migration into the tissue. 
IL-6. IL-6 is synthesized as a precursor 
protein. Monocytes express at least five 
different molecular forms of IL-6 with 
molecular masses of 19- to 26 kDa. The 
promoter gene for IL-6 contains many 
different regulatory elements allowing the 
induction of gene expression by many 
stimuli. IL-6 is a multifunctional cytokine 
that regulates acute phase response and 
inflammation, immune response and 
hematopoesis [113].  
IL-8. IL-8 is member of the CXC 
chemokine family, which primarily 
mediate the activation and migration of 
neutrophils into tissue from peripheral 
blood by acting as chemo-attractants [114, 
115]. IL-8 can also activate neutrophils to 
degranulate and cause tissue damage. IL-8 
is produced via processing of a precursor 
protein. In its processed form IL-8 has a 
molcular weight of only 8-to 11 kDa. It is 
produced by various cells including 
monocytes, macrophages, fibroblasts, and 
epithelial cells. The synthesis of IL-8 is 
strongly enhanced by IL-1 and TNF-?
[116].
IL-18. IL-18 belongs to the IL-1 family 
and is synthesiezed as a precursor, 
requiring caspase-1 for cleavage into the 
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active form. The active IL-18 molecule has 
a molecular weight of 18 kDa [117]. IL-18 
is a pro-inflammatory and pro-apoptotic 
cytokine produced by macrophages, 
monocytes, keratinocytes and epithelial 
cells. It stimulates the production of IL-1β, 
TNF-α and IFN-γ [62, 118, 119].  
There is a constitutive secretion of IL-1α, 
IL-1β, IL-6 and IL-8 in cervico-vaginal 
fluids of women in childbearing age with a 
Lactobacillus-dominated microbiota [120-
122]. A local increase of an array of proin-
flammatory cytokines and chemokines has 
been reported in BV, chorio-amnionitis 
[123] [124-126], in spontaneous preterm 
labour and PTB [29], and in infection with 
Neisseria gonorrhoeae [122].  
Despite the lack of clinical inflammation in 
BV, the levels of IL-1 and IL-8, but not IL-
6, are increased in vaginal and cervical 
secretions [124, 127, 128] [120, 121, 125].     
In preterm labor, however, significantly 
elevated cervical IL-6 and IL-8 levels are 
associated with microbial invasion of the 
amniotic cavity or chorioamniotic memb-
ranes, and with histological chorio-
amnionitis [129-131]. 
 
 
 
2.3 Secretory leukoprotease 
inhibitor, SLPI 
 
SLPI was originally isolated from the 
secretions of patients with chronic obst-
ructive pulmonary disease [132]. SLPI is a 
cationic acid stable serine protease 
inhibitor of the whey acidic protein-like 
family with a strong affinity for chymase, 
chymotrypsin, elastase, proteinase 3, 
cathepsin G and tryptase (fig. 3) [132-134]. 
Additionally, it has also been shown to 
exert antimicrobial, antiviral and antifungal 
activities [135-137]. SLPI also appears to 
be an important regulator of the 
inflammatory response by suppressing 
NFkB activation with resultant inhibition 
of peptide mediators, cytokines and 
chemokines [138-140]. It is a 11.7 kDa 
protein, consisting of 107 amino acids 
organized in two homologous, whey acidic 
protein four-disulfide core (WFDC) 
domains, of 53 and 54 amino acids, 
respectively (fig 2) [132, 141].  
The gene for SLPI is located on chro-
mosome 20q12–13.1 in humans. The anti-
protease active site of SLPI is located on a 
loop (residues 67–74) of the carboxyl-
terminal domain (fig 2) [142, 143] whereas 
the antimicrobial activity of SLPI has been 
found to be located in the amino-terminal 
domain [144, 145] [135]. SLPI is produced 
by epithelial cells, macrophages, and 
neutrophils, and is found in large quantities 
in bronchial-, cervical-, and nasal mucosa, 
saliva, and seminal fluids [48] [52, 139, 
142, 143, 146]. 
 
 
2.3.1 SLPI in diseases 
 
In women suffering from STDs or BV, 
dramatically reduced SLPI levels have 
been reported in vaginal fluid [91, 147].  
SLPI have been shown to prevent HIV 
transmission in macrophages by the 
binding to annexin II, a cellular cofactor 
supporting macrophage HIV-1 infection 
[148]. In addition, low levels of vaginal 
SLPI have been associated with a high 
transmission rate of HIV to the infant at 
delivery in pregnant women with a HIV-1 
infection [147]. 
In patients with inflammation in the lungs 
due to the hereditary disease cystic 
fibrosis, which affect exocrine glands of 
the lungs, liver, pancreas and intestines, the 
inhalation of aerosolized SLPI was shown 
to reduce IL-8 and neutrophil elastase in 
the bronchoalveolar lavage fluid [149]. 
Furthermore, an inverse correlation of the 
concentration of SLPI and neutrophil 
elastase in lung secretions has been 
reported in patients with chronic 
obstructive pulmonary disease [150, 151]. 
In the gut, an impaired induction of SLPI 
as well as other AMPs has been reported in 
Crohn's disease [152, 153].  
Moreover, people with a Helicobacter 
pylori infection exhibited a strong decline 
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in antral SLPI levels compared to H. 
pylori-negative subjects and subjects from  
 
 
 
 
 
 
whom H. pylori had been eradicated [154]. 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 3. Upper part: ribbon diagram of the 3D structures of SLPI. The side-chain 
Leu72 of SLPI is shown in green. The disulfide bonds are colored yellow. Below: 
molecular surfaces of SLPI in the same orientation as in the figure above colored 
according to the electrostatic surface potential (blue, positive regions; red, negative 
regions) (modified from T Moreau et al 2008).  
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AIMS OF THE STUDY 
The major aim of the thesis was to explore the interactions between microorganisms and host 
cells with regard to vaginal opportunistic bacteria but also with regard to lactobacilli and their 
influence on local immune defence factors. The specific aims of the studies were: 
• To investigate virulence features of Prevotella bivia, a gram negative rod commonly 
found in BV, 
• To analyse some of the most pre-dominant vaginal Lactobacillus spp in their ability to 
regulate innate immune factors such as SLPI and cytokines in cervical epithelial and 
monocytic cells, 
• To analyse the effect of SLPI on the pro-inflammatory cytokine response induced in 
cervical epithelial cells.  
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4. MATERIALS AND 
METHODS
Cell lines and cell cultivation conditions 
(I, II, III) 
The cervix epithelial cell line (HeLa) (I, 
III) and the human monocyte cell line 
(THP-1) (II) were obtained from the 
American Type Culture Collection 
(ATCC). HeLa cells were grown in culture 
flasks at 37°C in 5 % CO2 in Dulbeccos 
MEM (DMEM) (I)   (Biochrome, Berlin, 
Germany) or in Eagle’s MEM (III) (PAA 
Laboratories, AU) both supplemented with 
10 % fetal bovine serum, 100 mM sodium 
pyruvate, and 200 mM L-glutamine (all 
from Sigma-Aldrich, St.Louis, Missouri, 
USA).
THP-1 cells were grown in culture flasks 
at 37°C in 5 % CO2 in RPMI 1640 
medium (Invitrogen, Paisley, UK) 
supplemented with 10 % fetal bovine 
serum, 100 mM sodium pyruvate,  and 200 
mM HEPES buffer (all from Sigma-
Aldrich St.Louis, Missouri, USA).  
Bacterial strains, culture conditions and 
concentration determination (I, II, III) 
The bacterial strains and culture conditions 
used in the studies are listed in Table I. 
The bacteria were harvested for cell 
stimulation assays, transferred into 10 ml 
phosphate buffered saline (PBS) and 
washed once by centrifugation (2000 x g 
for 10 min.). Determinations of bacterial 
concentrations were done spectrophoto-
metrically (WPA CO75 Colorimeter, 
Cambridge, UK), at 590 nm, using 
standard-curves for each bacterial species, 
wherein the OD correlated to the number 
of bacteria per ml.  
In some experiments, lactobacilli were 
killed by ultra violet (UV) light, in which 
the bacterial suspension was transferred to 
a 6-well plate and placed on a shaker in 
UV light for 18 minutes. A verification of 
UV inactivation of the bacteria was 
performed by culturing.  
Bacterial adhesion assay (I) 
The bacterial adhesion analysis was 
performed according to Adlerberth et. 
al.[155] with some modifications. In short, 
HeLa cells were cultured to a confluent 
cell layer in DMEM medium supplemented 
with 10 % Cosmic calf™ serum (HyClone 
laboratories inc., Utah, USA), 200 mM L-
glutamine and 100 mM sodium-pyruvate, 
in 25 ml bottles. The cells were detached 
by incubation with 54mM EDTA solution 
for 10 minutes at room temperature and 
washed twice in DMEM. Finally the cell 
concentration was adjusted to 5 x 106 cells 
/ml. P. bivia strains were cultured on 
Brucella agar (BBL Microbiology system, 
Cockeysville, MD, USA), anaerobically, at 
37°C, in 95 % N2 and 5 % of CO2, for two 
days. The bacteria were harvested and 
washed once in Hanks balanced salt 
solution (HBSS). The bacterial concen-
tration was adjusted to 5 x 109 bacteria per 
ml by determination of the concentration 
by spectrophotometry, where OD 0.2 
corresponded to 2 x 108 bacterial cells per 
ml. A volume of 100 μl of each of the cell 
and bacterial suspensions were mixed 
together in a tube with 300 μl of HBSS and 
incubated, with rotation, for 30 minutes, at 
4°C or 37°C. The cells were subsequently 
washed twice by centrifugation, at 1000 
rpm. The cells were subsequently washed 
twice by centrifugation at 1000 rpm for 10 
minutes and re-suspended in HBSS. The 
remaining cell pellet was mixed with one 
drop of Histofix (Histolab AB, Sweden). 
Bacterial adhesion to the cells was 
evaluated by interference microscopy 
(Nikon Optiphot, Nikon PlanApo 500 x 
magnification), using the calculation of the 
mean number of adhering bacteria to forty 
cells.
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Table I
Bacterial strains Source 
CCUG* number 
(name in papers) Culture medium** 
Prevotella bivia FGT ? 34045       (P45) Brucella agar 
- ” -         - ” - 34046        (P46)    - “ -
- ” -         - ” - 34047        (P47)    - “ -
- ” -         - ” - 33961        (P61)    - “ -
- ” -         - ” - 9557♣        (P57)    - “ -
Lactobacillus iners - ” - 28746♣ Chocolate agar 
- ” - - ” - 44030        (003)    - “ -
- ” - - ” - 44065    - “ -
- ” - - ” - 44119        (119)    - “ -
Lactobacillus jensenii - ” - 35572♣    - “ -
- ” - - ” - 44003        (003)    - “ -
- ” - - ” - 44054    - “ -
- ” - - ” - 44149    - “ -
- ” - - ” - 44151        (151)    - “ -
Lactobacillus gasseri not known 31451♣    - “ -
- ” - FGT 44072    - “ -
- ” - - ” - 44076    - “ -
- ” - - ” - 44081    - “ -
 - ” - 44082     - “ - 
Lactobacillus crispatus - ” - 44016 MRS agar
- ” - - ” - 44073    - “ -
- ” - - ” - 44117        (117)    - “ -
- ” - - ” - 44118    - “ -
Escherichia coli 
O6:K13 
Örskov. Su 4344 11308 Horse blood agar 
Escherichia coli
HB101 
Dr N. Strömberg 
(University of Umeå).
- - “ - 
? Female genital tract
* Culture Collection, University of Gothenburg
** All bacteria except E.coli were grown under anaerobic conditions in 95 % N2 and 5 % CO2,  at 37°C.
     E.coli was cultured under aerobic conditions, at 37°C.
♣ Type species strains 
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A modification of the adhesion assay was 
performed in order to simulate the invasion 
assay. In the modified assay, the HeLa 
cells were incubated on a slide chamber 
(Lab-Tek, Chamber Slide System, US) and 
the cells remained adherent during the 
incubation with the bacteria. 
Invasion assay (I) 
The assay is based on the varying 
bactericidal effect of antibiotics on extra- 
and intracellular located bacteria [156]. All 
experiments with different P.bivia strains 
were performed under anaerobic 
conditions while control experiments with 
the non-adhesive E.coli HB101 were 
accomplished in normal atmosphere. 
Bacteria were scraped off agar plates, 
washed once by centrifugation in 
phosphate buffered saline, pH 7.2 (PBS), at 
3000 x g, and suspended in DMEM 
without serum and penicillin-streptomycin 
(PEST) at a concentration of 1x107
bacteria/ml. HeLa cells were washed in 
PBS, infected with 500 μl bacterial 
suspension per microtitre well of either P.
bivia or E. coli and incubated, at 37°C, for 
2 h. The epithelial cells were subsequently 
washed three times with PBS and 
incubated for 3 h with DMEM containing 
metronidazole (0.1 mg/ml) and gentamicin 
(0.5 mg/ml), in order to prevent 
extracellular bacteria from further 
multiplication. HeLa cells were thereafter 
washed three times in PBS and incubated 
with 1 ml sterile distilled water, for 10 
min, to lyse the membranes of the 
epithelial cells. Released intracellular P.
bivia was plated on Brucella agar and E.
coli on blood agar. Cultures on Brucella 
agar plates were incubated for 7 days and 
those on blood agar plates were incubated 
for 24 h.  The invasion capacity was 
quantified by counting colonies and 
expressed as colony forming units (CFU) 
per well.
In order to estimate the effects of 
antibiotics and medium on bacterial 
survival, the same number of bacteria of 
each strain was incubated without 
epithelial cells, in DMEM supplemented 
with metronidazole and gentamicin for 3 h. 
All the experiments were performed in 
triplicates with, at least, three independent 
runs per strain.
Cell stimulation assays (I, II, III) 
UHeLa cells (I, III). UHeLa cells were grown 
in supplemented medium and transferred to 
24-well plates, at a density of 105 cells per 
well the day before cell experiment. Prior 
to cell-stimulation by bacteria, the cells 
were washed once in fresh homologous 
medium. Thereafter, 450 μl of homologous 
medium, supplemented as above except for 
the addition of 5 % heat-inactivated FCS 
instead of 10% normal FCS, and 10 μg/ml 
of metronidazole (I) or 200 U/ml of 
penicillin-streptomycin (PEST) (I, III), to 
prevent bacteria from further 
multiplication, were added to each well. 
Bacterial suspensions, 50 ?l of various 
concentrations, were then added to each 
well and the cells were subsequently 
incubated at 37° C, in 5 % CO2, for 
different time periods. In one experiment, 
the stimulation of the cells with bacteria 
was performed in culture flasks (250 ml), 
instead of a 24-well plate, in order to 
obtain a higher number of cells.  
UTHP-1 cells (II).UTHP-1 cells were pre-
stimulated for 16 hours with 100 U/ml of 
interferon gamma (IFN-γ) (Roche 
Diagnostic, Mannheim, Germany) in 
RPMI medium supplemented with 10 % 
fetal bovine serum, 100 mM sodium 
pyruvate and 200 mM HEPES buffer 
(Sigma-Aldrich St.Louis, Missouri, US). 
The medium was removed by 
centrifugation at 160 x g, and the cell pellet 
was re-suspended in assay medium (RPMI 
1640 medium supplemented with 5 % 
heat-inactivated fetal bovine serum. The 
cell concentration was adjusted to 1x106
cells/ml and 450 μl of the cell suspension 
were transferred to 24-well plates prior to 
stimulation with bacteria. 
Cell supernatants and cells were 
subsequently collected for further analysis 
by ELISA or PCR.  The supernatants were 
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centrifuged, at 10’000 rpm, and kept 
frozen at -70°C until analyses were 
performed. For PCR, HeLa cells (III) were 
detached, by adding 0.1 ml of 0,54 mM 
EDTA solution per well, for 10 minutes, at 
room temperature. Collected non-adherent 
THP-1 cells (II) and detached HeLa cells 
were washed once in 1 ml PBS, 
centrifuged at 160 x g, and the pellet was 
re-suspended in RNAlater (Ambion, 
Cambridgeshire,UK) and stored at -20°C
until cDNA preparation for PCR was 
performed.   
In some experiments (III), recombinant 
human SLPI (rh-SLPI) (R&DSystems, 
Abingdon, UK) was added to the HeLa 
cells prior to the addition of bacteria. Cells 
and supernatants were then collected and 
treated as described above.
Electron microscopy (I) 
Transmission electron microscopy (TEM) 
was performed in order to confirm the 
intracellular location of internalized 
bacteria. HeLa cells cultured in 35 mm 
petri-dishes were infected with P.bivia P47 
and treated as described for the invasion 
assay. After a total of 5 h incubation, the 
cultures were washed four times in PBS. 
The HeLa cells were detached from the 
plastic surface with trypsin/EDTA (0.05% 
/0.5 mM) solution. Fixation was performed 
by addition to the cell suspension, 2.5% 
glutaraldehyde in 0.05 M Na cacodylate, 
for 45 min. Cells were thereafter pelleted 
and fixed, with 1% OsO4 in 0.1 M Na 
cacodylate, for 30 min. Ethanol 
dehydration and propylene oxide treatment 
were subsequently performed by 
successive gentle re-suspensions and 
centrifugations. The cells were finally 
infiltrated with Agar 100 resin in BEEM 
capsules. The ultrathin sections were 
contrasted with lead citrate and uranyl 
acetate before examination, using a Zeiss 
CEM 902 electron microscope.  
Scanning electron microscopy (SEM) and 
TEM were used for detection of adhesion 
structures on P. bivia P47. Bacteria were 
grown anaerobically, for 3 days, at 37°C,
on trypticase soy agar plates supplemented 
with hemin and menadione. Bacteria were 
then gently scraped off the plates and 
suspended in reduced transport fluid, 
according to the methods of Leyng et. al. 
and Salam et. al. [157, 158]. Prior to TEM, 
bacteria were fixed in a suspension 
containing an aldehyde mixture (2% 
paraformaldehyde + 2.5% glutaraldehyde 
in 0.05 M Na cacodylate buffer, pH 7.2) 
and diluted 1:1 with phosphate buffered 
saline (PBS, pH 7.4). The suspension was 
then washed and kept in PBS. Five ?l 
droplets of the suspension were applied on 
Formvar coated copper grids for 1 min. 
After a brief rinse the adhering bacteria 
were negatively stained, with 0.5% uranyl 
acetate in water, for 10-30 sec, after which 
the staining solution was removed with a 
filter paper. The stained specimens were 
examined, using a Zeiss 902 electron 
microscope. Prior to SEM, 250 ?l drops of 
bacteria, fixed and washed as above, were 
transferred to poly-l-lysine treated gold 
coated Thermanox cover-slips, for 30 min, 
to allow the bacteria to adhere to the 
surface. After rinsing with PBS, the cells 
were prepared for SEM with the OTOTO 
method, according to Friedman et. al. 
[159], comprising repeated treatments with 
osmium tetroxide and thiocarbhydrazide. 
The cover-slips were dehydrated in ethanol 
and infiltrated with hexamethyldisilazane, 
which was allowed to evaporate in a fume 
hood. The dried specimens were mounted 
on aluminum SEM stubs and examined, 
without thin film metal coating, using a 
Zeiss 982 Gemini SEM. 
Cytokine and SLPI detection by 
Enzyme-Linked ImmunoSorbent Assay 
(ELISA) (I, II, III) 
Enzyme-Linked Immuno Sorbent Assay 
(ELISA) was used for quantification of 
cytokines and SLPI in the cell 
supernatants. Primary mouse monoclonal 
anti-human and secondary polyclonal 
biotinylated goat anti-human antibodies 
against IL-1α, IL-6, IL-8, IL-18 and TNF-
α and their respective recombinant 
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standards were obtained from R&D 
Systems (Abingdon, UK) for cytokine 
quantification. The sandwich ELISA assay 
was done according to the manufacturer’s 
description except that alkaline 
phosphatase conjugated streptavidin 
(Extravidin, Sigma-Aldrich, St.Louis, 
Missouri, USA) diluted 1:1000 was used 
instead of streptavidin Horse-Redish-
Peroxidase (HRP), and as substrate 
solution, para-nitrophenyl phosphate 
(pNPP, 1 mg/ml, Sigma-Aldrich, St.Louis, 
Missouri, USA) in diethanolamin buffer 
(pH 9,8) was used. Colour development 
was analysed spectrophotometrically at 
405 nm. An ELISA assay for SLPI 
quantification was set up with the 
following antibodies from R&D Systems; a 
primary monoclonal mouse anti-human 
SLPI (MAB1274) at a concentration of 4 
μg/ml; a secondary biotinylated goat anti-
human SLPI (BAF1274), at 20 ng/ml; and 
recombinant human SLPI (1274-PI), as a 
standard. The detection limit was 78 pg/ml. 
The assay procedure was performed as 
described for the cytokines. 
RNA extraction and cDNA synthesis (II, 
III)
Total cellular RNA was prepared by using 
the RNeasy Mini Kit (QIAGEN, Hilden, 
Germany) following the manufacturer’s 
protocol. Samples were lysed and 
homogenized in the presence of a 
guanidine isothiocyanate buffer. To 
remove contaminating DNA, eluted total 
RNA was treated with RNase free DNase 
I, according to the manufacturer’s 
description (DNA-free Kit, Ambion, 
Cambridgeshire,UK). Total RNA was 
subsequently quantified by measuring the 
ratios of optical densities at 260 nm and 
280 nm. The RNA integrity for each 
sample was visualised by electrophoresis 
on a 3 % agarose gel containing 0.02 % 
SybrGreen.
cDNA was prepared from 1 μg of total 
RNA, using a mixture of 100 pmol of 
random hexamer, pd(N)6 (GE Healthcare, 
UK), first strand reaction buffer 
(Invitrogen AB, Sweden), 0.5 mM of 
dNTP mix (GE Healthcare, UK), 1 U/μl of 
ribonuclease inhibitor (RNasin, Promega, 
US) and 13.3 U/μl of reverse transcriptase 
(SuperScript, Invitrogen, Paisley, UK), 
followed by incubation at 42°C, for 1 hr, 
and termination of reaction by incubation 
at 70°C for 10 min. 
Polymerase chain reaction (PCR) 
analysis (II, III) 
Relative quantification of SLPI, IL-8, MD-
2, CD-14, TLR-2, -3,-4, and -5 mRNA 
expression was analysed by real time PCR 
(LightCycler, Roche). The primers for the 
PCRs are listed in Table II. 
Glyceraldehyde-3-phosphate-dehydroge-
nase (GAPDH) was used as a house-
keeping gene (referred to as reference). 
The primers for IL-8 were obtained from 
Clontech Laboratories (Paolo Alto, CA, 
US) and all the other primers were 
obtained from TibMol (Berlin, Germany). 
A LightCycler FastStart DNA Master 
SYBER Green 1 Kit (Roche Diagnostics, 
Mannheim, Germany) was used for the 
PCR, according to the manufacturer’s 
protocol. The PCRs were carried out in a 
total volume of 20 μl, containing 2 μl
cDNA, 3.5 mM MgCl2 and 0.5 μM of each 
primer.  
Relative quantification calculation of the 
samples was performed by using the 
Relative Quantification LightCycler soft-
ware (Roche), by which the results were 
normalized to a calibrator and expressed as 
the sample/reference ratio of each sample 
normalized by the sample/reference ratio 
of a calibrator. A macrophage cell line 
(MonoMac) was used as a positive control 
in analyses of the MD-2, CD-14, and TLR-
2,-4, -5 mRNA expression.  
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Table II. Primer pairs used in the PCR  
______________________________________________________________________________ 
Product        Forward primer                                       Reverse primer                                      Product size (bp) 
__________________________________________________________________________________________ 
TLR 2            GCCAAAGTCTTGATTGATTGG               TTGAAGTTCTCCAGCTCCTG                             347 
TLR 4            AAGCCGAAAGGTGATTGTTGT              ATTGCATCCTGTACCCACTGTT                        310 
TLR 3            AAATTGGGCAAGAACTCACAGG          GTGTTTCCAGAGCCGTGCTAA                          320  
TLR 5            CCATCCTCACAGTCACAAAGTT            TCTAAGGAAGTGTCTGCTCACAA                    326 
MD-2             CTCAGAAGCAGTATTGGTC                    GTTGTATTCACAGTCTCTCCCT                        295 
CD-14            GGTGCCGCTGTGTAGGAAAGA             GGTCCTCGAGCGTCAGTTCCT                          454 
SLPI              GCTGTGGAAGGCTCTGGAAA                 TGCCCATGCAACACTTCAAG                            298 
IL-8               ATGACTTCCAAGCTGGCCGTGGCT       TTCTCAGCCCTCTTCAAAAACTTCTC              289 
GAPDH        GGCTGCTTTTAACTCTGG                         GGAGGGATCTCGCTCC                                      190 
____________________________________________________________________________________________________
Absorption Assay (III) 
L. iners 119 and E. coli were used at a 
concentration of 109 bacteria per ml, in 
combination with different doses of 
recombinant human (rh) SLPI (R&D 
Systems, Abingdon, UK), to assess 
bacterial absorption of SLPI. The bacteria 
were grown and treated as described for 
the cell assays. The combination of 
bacteria and SLPI was performed in cell 
assay medium (Eagle’s MEM comp-
lemented as for the cell assay) and 
incubated at 37°C, for 2 h, and then at 4°C,
for 16 h. The samples were then 
centrifuged at 10’000 rpm and the 
supernatants were collected for analysis of 
SLPI by ELISA.
Western Blot (III)
HeLa cell- supernatants from cells un-
stimulated or stimulated with L.iners 119, 
at concentrations of 107 or 109 bacteria per 
ml, for 20 h, were analysed for SLPI by 
Western Blotting. Electrophoresis of 
samples was performed, using precast 
NuPage Novex 10 % Bis-Tris mini gel 
(Invitrogen, Carlsbad, CA,USA) in 1 X 
SDS NuPage MES Running buffer 
(Invitrogen), according to the 
manufacturer’s description. Recombinant 
human SLPI (R & D Systems, Abingdon, 
UK) was used as a positive control, at a 
concentration of 0.5 μg/ml.  A pre-stained 
standard, SeeBlue Plus2 (Invitrogen) was 
used, as a molecular weight marker. 
Protein transfers to nitrocellulose 
membranes were conducted, using the 
iBlot Dry Blotting System (Invitrogen), 
according to the manufacturer’s 
description.  The nitrocellulose membrane 
was blocked, using Blocking Buffer 
(Sigma, St. Louis, MO, USA), for 60 min, 
and was thereafter and in sequential steps 
washed three times, for 5 min each, in 
Tris-buffered saline containing 0.1 % 
Tween 20 (TTBS). The membranes were 
incubated for 120 min, with an affinity 
purified goat anti human SLPI antibody (R 
& D Systems, Abingdon, UK), at a 
concentration of 0.1 μg/ml, followed by 
incubation for 45 min,  with biotinylated 
rabbit anti goat immunoglobulins 
(Southern Biotechnology Associates, Ink. 
Birmingham, AL, USA), diluted 1:1000 in 
TTBS. The membranes were then 
incubated for 45 min with Extravidin 
Alkaline Phosphatase (Sigma), diluted 
1:5000 in TTBS. Band visualization was 
performed, using Western Breeze 
Chemiluminescent Substrate (Invitrogen) 
containing 5 % Chemiluminescent Subst-
rate Enhancer (Invitrogen) with a sub-
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sequent imaging of membranes in Gene 
Gnome Bio Imaging (Syngene) for 20 min.     
5. RESULTS 
Adhesion, invasion and intracellular 
location of Prevotella bivia in HeLa cells 
(I)
Five strains of the opportunistic pathogen 
P.bivia, all isolates from women with BV, 
were investigated for their capacity to 
adhere to and invade cervix epithelial cells 
(HeLa). 
UInvasion
The number of intracellular bacteria 
isolated from infected HeLa cells varied 
between the five P.bivia strains (fig. 1). 
The P. bivia strain 46 (P46) exhibited the 
lowest number of intracellular bacteria per 
well corresponding to 60 bacteria per 
1x105 HeLa cells. The strains P61 and P57 
showed a 3-10 fold higher invasion 
capacity, corresponding to approximately 
2-6x102 bacteria per 1x105 cells, while the 
number of intracellular P45 (3x103 bacteria 
per 1x105 cells) was 40 times higher than 
that of P46. Strain P47 gave rise to the 
highest number of bacteria per well 
(approximately 7x103 bacteria per 1x105
cells), being 120-fold higher than that of 
P46. The invasion efficiency ranged from 
0.002% (P46) to 0.2% (P47) (the ratio of 
the number of intracellular bacteria to the 
total inoculum) (fig. 2). 
UAdhesion
The five isolated strains of P.biva were 
investigated for their capacity to adhere to 
HeLa cells by interference microscopy.  
The adhesion capacity ranged between 14-
22 bacteria/cell (fig 3). There was no 
significant difference in the adhesion 
capacity between the most invasive (P47) 
and the least invasive strain (P46) when the 
bacteria were added in different 
concentrations to the HeLa cells. The 
numbers of adhering bacteria per cell 
increased in a dose-dependant manner for 
both strains and reached a plateau at a ratio 
of 100:1 bacteria per cell (fig. 4). 
No correlation was established between 
intracellular survival and adhesion for the 
five strains. Thus, the strain giving rise to 
the highest number of intracellular 
bacteria, P47, showed no increased 
adhesion capacity in comparison with the 
other strains (fig. 1 and 3).
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 Fig.2 Invasion of HeLa cells by P.bivia (P47).
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 105. The mean number of CFU recovered from
  HeLa cells infected by P47 is indicated. The
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Fig.1. Recovery of intracellular P.bivia in HeLa cells. 
The mean number of CFU in HeLa cells infected by 
P.bivia per well. The bars represent the standard 
error of the mean (SEM). 
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UIntracellular location of P.biva
The intracellular location of the most 
invasive strain P47 was investigated by 
electron microscopy. Incubation of HeLa 
cells with P47 was performed as described 
for the invasion assay. An intracellular 
location of P47 was seen in phagosome-
like vesicles, as analyzed by transmission 
electron microscopy (TEM) (fig. 5). 
UAdhesion features of P.bivia
The P47 strain was further investigated for 
morphological adhesion features on the 
cell surface by TEM. No visible adhesion 
structure like fimbriae was visible on the 
surface of P47 (fig.6). 
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Fig.4 Adhesion of P.biva (P46 and P47) to HeLa
cells.The mean nuber of adhering bacteria per cell
is indicated.The bars respresent the standars error
of the mean (SEM).
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Fig.5. TEM micrograph of intracellular 
localization of P.bivia (P47) in HeLa cells.
Fig. 6 TEM analysis of adhesion structures on 
P.bivia (P47). 
Fig.3. Adhesion of P.bivia to HeLa cells, ratio 
1000:1 bact./cell. The number of bacteria 
adhering to HeLa cells was analysed by 
interference microscopy. The bars represent 
SEM. 
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Cytokine inducing capacity of P.bivia (I) 
Since P.bivia is associated with upper 
genital tract infection and BV, which often 
is a subclinical syndrome, the ability of 
this Gram-negative anaerob to induce a 
pro-inflammatory cytokine response in 
HeLa cells was investigated by ELISA. 
P46, P47, P57, and P61 were analysed for 
their cytokine inducing capacity in HeLa 
cells. Of the four tested P.bivia strains only 
P47 was able to stimulate, to a low but 
significant IL-6 and IL-8 response in HeLa 
cells, at a concentration of 100 bacteria per 
cell. This cytokine-inducing capacity of 
P47 was, however, approximately 2 % of 
that induced by E. coli. No detectable 
cytokine levels in the cell supernatant were 
obtained by any of the other P. bivia
strains tested (Table1). 
Table 1. The levels of IL-6 and IL-8 in supernatants from HeLa cells stimulated  
with P. bivia or  E. coli.   
      
Strain                            UIL-6 (pg/ml)                          IL-8 (pg/ml) 
 bacteria 6 h 20 h    6h   20h 
 per cell 
      
P46   10 < <*    <    <* 
 100 < <    <    < 
P47   10 < <    <    < 
 100 < 17 ± 5    <    57 ± 17 
P57   10 ND ND   ND    ND 
 100 < <   ND    ND 
P61   10 ND ND   ND    ND 
 100 < <   ND    ND 
E.coli   10 75 ±14 430 ±26 343 ±91   470 ± 45 
 100 ND 730 ±110 252 ±115 2380 ± 120 
      
 ND= not determined  
* Background levels of IL-6 or IL-8  
SLPI regulation in THP-1 cells (II) and 
HeLa cells (III) stimulated with vaginal 
lactobacilli
In order to investigate the effects of 
lactobacilli on the regulation of SLPI 
secretion we incubated THP-1- (II) or 
HeLa cells (III) together with the four most 
predominant Lactobacillus species 
(L,crispatus, L.jensenii, L.gasseri, and
L.iners) of the female genital tract of 
healthy women.
UTHP-1 cells (II)
THP-1 cells were incubated with isolates 
of L.iners, L, crispatus, L. jensenii and L. 
gasseri at different doses for 20 h and the 
SLPI levels were subsequently measured in 
cell supernatants.
A significant up-regulation of the mean 
SLPI secretion, compared to constitutive 
levels, was observed when stimulating the 
cells with L. iners at 106 – 108 bacteria per 
ml (fig.7 and 8). In contrast, a down-
regulation of the SLPI levels was seen in 
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cells incubated with L.crispatus at 108 and 
109 bacteria per ml or with L. gasseri at 
109 bacteria per ml (fig.7).  
L.jensenii did not alter the constitutive 
secretion of SLPI in the cells. The most 
pronounced differences in the induction of 
SLPI secretion were seen between L. iners 
and L. crispatus at concentrations of 108
and 109 bacteria per ml (p = 0.0002 and p 
= 0.0001 respectively). 
The capacity of one L. iners strain to in-
duce a SLPI response in THP-1 cells was 
also compared to that of Gram-negative 
bacteria, such as the uro-pathogen, E. coli.
THP-1 cells were incubated with L. iners
or E. coli at different doses of bacteria per 
ml for 20 hours (fig 8). An up-regulation of 
SLPI, over constitutive levels, was ob-
tained by L. iners at 106 to 108 bacteria per 
ml. At 109 bacteria per ml the SLPI levels 
decreased below constitutive levels when 
stimulated with either L. iners 119 or E.
coli, although the decrease was not 
significant for E. coli. A significant differ-
rence between L. iners 119 and E. coli was 
obtained in their capacities to regulate the 
SLPI secretion in the cells, at 108 bacteria 
per ml.   
The kinetics of the SLPI secretion in THP-
1 cells stimulated by L. iners, at a con-
centration of 107 bacteria per ml, showed a 
significant increase of SLPI secretion over 
constitutive at 6 and 20 h of incubation 
(fig.9 a). Analysing the kinetics and dose 
response of the SLPI mRNA expression in 
cells stimulated with L. iners revealed an 
initial increase over constitutive level 
already at 1 h of incubation for all tested 
concentrations of bacteria. However, at 2 h 
and 20 h of incubation the mRNA exp-
ression returned to the same level or below 
that of the constitutive expression for all 
the doses tested (fig.9 b). This was in 
contrast to the up-regulation of SLPI 
protein levels at these time points by L.
iners at 107 bacteria per ml (fig.9 a). 
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Fig.8. SLPI secretion in THP-1 cells 
stimulated for 20 h with E.coli (?) or L. 
iners 119 (?) at different doses. The 
SLPI secretion is presented as fold 
change over constitutive levels. The bars 
in each point represent SEM.  
Fig.7. SLPI levels analysed by ELISA in 
supernatants from THP-1 cells stimulated 
for  20 h with isolates of L.iners (?, four 
isolates), L.gasseri (?, five isolates),
L.jensenii (∇, five isolates), and 
L.crispatus (?, four isolates) The broken 
line shows the constitutive secretion level 
in the cells at 20 h. The bars in each point 
represent SEM.  
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Table 2. SLPI and cytokine levels analysed by ELISA in supernatants from HeLa cells stimulated with each 
Lactobacillus strain alone or in combination with E.coli at a total concentration of 108 bacteria per ml. The 
control is supernatant from un-stimulated cells. The standard error of mean (SEM) of triplicates are indicated. 
L.jensenii      003            48,8 ± 5,8    39,8 ± 2,1          0,17 ± 0,03    5,05 ± 0,36       0,20 ± 0,01   5,16 ± 0,21 
                     151             57,8 ± 0,9    39,6 ± 0,4          0,07 ± 0,01    6,38 ± 0,34       0,10 ± 0,01   4,33 ± 0,36         
L.crispatus   117             30,8 ± 0,5    22,0 ± 0,3          0,46 ± 0,05    4,69 ± 0,10       0,66 ± 0,03   6,87 ± 0,42 
L.iners          030             52,6 ± 1,7    40,8 ± 1,8          0,25 ± 0,01    6,68 ± 0,06       0,18 ± 0,01   9,66 ± 0,25 
                     119             59,9 ± 2,4    40,7 ± 1,0          0,09 ± 0,01    6,79 ± 0,39       0, 07 ± 0,01   8,39 ± 0,13 
E.coli                               42,1 ± 1,2         NA*              4,98 ± 0,9             NA              3,13 ± 0,19          NA    
Control                                       66.8 ± 4,1                                        0                                                 0 
*NA = not applicable 
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Fig. 9. SLPI protein secretion and mRNA expression in THP-1 cells stimulated with L.iners 119.  a) 
Kinetics of SLPI protein secretion in cell supernatants un-stimulated (?) or stimulated (?) with 
L.iners 119 at 107 bacteria per ml for 1, 2, 6 and 20 h analysed by ELISA. b) Relative SLPI mRNA 
expression calculated as fold change over the constitutive expression level in THP-1 cells stimulated 
for 1, 2 and 20 h with different doses of L.iners 119. The bars in each point represent SEM.  
SLPI
ng/ml 
IL-6 
ng/ml 
IL-8 
ng/ml 
Bacterial strain 
Combined 
with E.coli 
Single 
strain
Single 
strain
Combined 
with E.coli 
Single 
strain
Combined 
with E.coli 
 25
UHeLa cells (III)
Since L.iners up-regulated and L. crispatus
down-regulated the secretion of SLPI in 
THP-1 cells at a concentration of 108
bacteria per ml we investigated whether 
SLPI would be regulated in the same way 
in HeLa cells. 
HeLa cells were incubated with isolates of 
L. iners, L. crispatus or L. jensenii at 108
bacteria for 20 h (Table 2). None of the 
isolates of L. iners (119 and 030) or 
L.jensenii (151) altered the constitutive 
secretion levels of SLPI in the cells. In 
contrast, L. crispatus (117) and L. jensenii
(003) significantly reduced the SLPI 
levels. L. crispatus (117) reduced the SLPI 
secretion as much as 54 %, compared to 
the constitutive level, and by 49 %, 
compared to the levels obtained by L.iners
(119) (p=0.0005 and p=0.003, respec-
tively). L.jensenii (003) also significantly
reduced the SLPI secretion, compared to 
the constitutive level (p = 0,0143). 
L. iners was also compared with E .coli in 
their effects on SLPI secretion in HeLa 
cells (fig.10). There were no differences 
observed in the SLPI levels in supernatants 
from cells stimulated with either L.iners or 
E.coli at 106 and 107 bacteria per ml 
compared to the constitutive levels in the 
cells (fig.10 a). A significant decrease in 
SLPI levels was, however, observed upon 
incubation with 108 and 109 E. coli per ml, 
and with 109 L. iners per ml (fig.1a). Thus, 
a tenfold higher concentration of L. iners
than E. coli was required to inhibit the 
secretion of SLPI to the same extent.  
The kinetics of SLPI secretion in HeLa 
cells incubated for different time periods 
with L. iners (107 or 109 bacteria per ml) or 
with E.coli (109 bacteria per ml) revealed a 
significant decrease in SLPI levels with 
109 bacteria per ml at 6 h (L. iners, p= 
0.0007; E. coli, p=0.0056) and at 20 h (L.
iners p > 0.0001; E. coli p > 0.0001), 
compared to constitutive levels (fig. 10 b).  
The expression of SLPI mRNA in HeLa 
cells stimulated with L. iners or E. coli did
not differ, compared to constitutive SLPI 
mRNA expression at 1 or 2 h of incubation 
(fig.11). However, at 20 h, the mRNA 
expression was significantly higher than 
the constitutive levels in cells incubated 
with L. iners or E. coli at 109 bacteria per 
ml (p= 0.0191 and p=0.0133, respectively). 
Additionally, there was a significant 
difference in the mRNA expression of cells 
incubated with 107 or 109 bacteria per ml at 
this time point. A negative correlation (r = 
- 0.9805, p = 0.0195) was established at 20 
h between SLPI mRNA and secreted SLPI 
protein levels.
Cytokine-induction in THP-1- and HeLa 
cells stimulated with L.iners, L.crispatus, 
L.jensenii and L.gasseri (I, II) 
As cytokines are a part of the local 
immune defence at mucosal surfaces we 
also investigated the ability of the chosen 
vaginal lactobacilli to evoke a cytokine 
response in THP-1 (II) and HeLa cells 
(III). 
UTHP-1 cells (II)
THP-1 cells were incubated with isolates 
of L.iners, L.crispatus, L.jensenii and
L.gasseri, at different doses, for 20 h. 
All isolates of the four Lactobacillus
species were capable to induce a cytokine 
response in THP-1 cells, although the 
levels varied among the species. At 
concentrations of 107 and 108 bacteria per 
ml the isolates of L.crispatus induced the 
highest secretion of TNF-α and IL-8, 
whereas isolates of L. iners induced the 
highest levels of TNF-α and IL-6 at 109
bacteria per ml (fig. 12 a, b and c). 
Significant differences between L.
crispatus and L. iners, L. gasseri or L. 
jensenii were obtained for the induction of 
TNF-α and IL-8, at 108 bacteria per ml, 
and between L. gasseri and L. crispatus,
for IL-6, at the same bacterial 
concentration. At 109 bacteria per ml, 
significant differences were observed 
between L.iners and L.crispatus for TNF-α
and between L.iners and
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Fig.10. SLPI secretion in HeLa cell supernatants stimulated with L.iners or E.coli. a) SLPI levels in cell 
supernatants analysed by ELISA after 20 h of incubation with different doses of L.iners or E.coli. b) Kinetics 
of SLPI levels in cell supernatants analysed by ELISA. The cells were incubated with L.iners at 107 or 109
bacteria per ml or E.coli at 109 bacteria per ml for different time points. The bars in each point represent SEM 
of triplicates of three independent experiments. ***P < 0.0001 
Fig.11. SLPI mRNA expression in HeLa cells incubated 
with different doses of L.iners or E.coli for 1, 2 or 20 h. 
The mRNA levels were analysed by PCR and expressed 
as fold change over constitutive level. The bars in each 
point represent SEM of triplicates of two independent 
experiments.  
** P = 0,0043,  * P = 0,0288  
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L. crispatus or L. gasseri for IL-6. Signi-
ficant differences were also obtained 
between L. jensenii and L. gasseri or L.
crispatus for the IL-18 at 109 bacteria per 
ml (fig. 12 a-d).  
UHeLa cells (III)
HeLa cells were incubated with isolates of 
L. iners, L. crispatus, and L. jensenii at 108
bacteria per ml, for 20 h. All the different 
lactobacilli strains induced in general very 
weak IL-6 and IL-8 responses (0.07 – 0.7 
ng per ml) in the HeLa cells stimulated 
with 108 bacteria per ml (Table 2).  
Since HeLa cells are known to secrete no 
or very low levels of cytokines in response 
to LPS we compared the cytokine response 
induced by L.iners to that of E.coli, which 
has previously been shown to evoke a 
cytokine response in HeLa cells (fig. 13) 
In comparison with E. coli, all the tested 
concentrations of L. iners induced very low 
levels of IL-6 and IL-8 in HeLa cells (fig. 
13 a). There was approximately a 10 – fold 
difference between E. coli and L. iners in 
the induction of IL-6 in cells stimulated 
with 107 to 109 bacteria per ml, and E. coli 
also induced a very strong IL-8 response at 
108 to 109 bacteria per ml.  The differences 
between the two bacterial species were 
however less in the induction of IL-6 than 
it was for IL-8 (fig, 13 b). 
SLPI and cytokine responses in THP-1
cells (II) or HeLa cells (III) co-
stimulated with Lactobacillus species 
and E. coli
Since LTA from lactobacilli of gut origin 
previously has been shown to down-
regulate a TNF-α response induced by LPS 
in THP-1 cells, we wanted to investigate 
whether the presence of lactobacilli could 
influence SLPI and cytokine responses 
induced by E. coli in our cells. Lactobacilli 
were added prior to E. coli to THP-1 cells 
or HeLa cells. The cells were subsequently 
incubated with a total concentration of 108
bacteria per ml for 20 hours.  
UTHP-1 cells (II)
SLPI secretion and mRNA expression 
The SLPI levels decreased significantly for 
all combinations of lactobacilli and E. coli
compared to the levels induced by the 
lactobacilli alone except for E. coli in 
combination with L. crispatus, wherein the 
SLPI levels were unaffected (fig.14a). The 
combination of L. jensenii 003 or L. iners
119 with E. coli also gave rise to SLPI 
levels below that induced by E. coli alone. 
While L. iners induced an up-regulation of 
the SLPI mRNA expression above the 
constitutive level at 1 h of incubation 
(fig.14 b), no such up-regulation was seen 
for the combination of L .iners 119 and E.
coli at the same time point. At 2 h the SLPI 
mRNA expression in the cells did not 
differ from the level induced by the 
stimulation of L. iners alone or in 
combination with E. coli.  At 20 h of 
incubation however, the mRNA expression 
was reduced compared to the constitutive 
expression for both L. iners 119 alone and 
in combination with E. coli.
Cytokines
In general, the co-stimulation of 
lactobacilli with E.coli induced stronger 
TNF-α, IL-8, IL-6 IL-18, and IL-1α (not 
shown) responses in THP-1 cells than 
those induced by each bacteria alone 
(fig.15). Synergy effects, i.e., significantly 
higher levels than the additive levels 
derived from each of the bacterial strains, 
were obtained for TNF- α by the 
combination of E.coli with either L.
jensenii 151 (p=0.0011), L. iners 030 
(p=0.0004) or L. iners 119 (p<0.0001) 
(fig.15 a). Positive synergy effects were 
also obtained for IL-8 responses by E. coli
in combination with either L. jensenii 003 
(p=0.0157), L. jensenii 151 (p=0.0046) or 
L. iners 119 (p=0.0358) (fig.15 b). The 
induction of IL-1α showed a similar 
pattern as for TNF-α and IL-8, with 
positive synergy effects by the  
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Fig. 12. Cytokine responses in THP-1 cells stimulated with isolates of L.iners (?, n=4), L.gasseri 
(?, n=5), L.jensenii (∇, n=5), L.crispatus (?, n=4) at bacterial concentrations of 107, 108 and 109
per ml after 20 hours of incubation. The a) TNF-α, b) IL-8, c) IL-6 and d) IL-18 levels in THP-1 
cell supernatants were measured by ELISA. The bars in each point represent SEM.  
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combination of E. coli and lactobacilli 
(data not shown).
In contrast, negative synergy effects were 
obtained by the combination of E.coli with 
L. crispatus 117 in the IL-8 response and 
for E. coli together with all lactobacilli 
except L. jensenii 151 in the IL-6 respon-
ses (p < 0.0001 – p = 0.0002) (fig.6 b and 
c). A similar pattern was also seen in the 
IL-18 responses for E. coli in combination 
with either L. jensenii 003 (p=0.0182), L.
iners 030 (p=0.0499) or L. iners 119 
(p=0.0301) (fig.15 d).
Fig.13. Cytokine secretion in HeLa cells stimulated with L.iners or E.coli at different 
concentrations for 20 h. a) IL-6 - and b) IL-8 levels in supernatants analysed by ELISA. The 
bars in each point represent SEM of triplicates of one representative experiment.  
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Fig. 14.  SLPI secretion and mRNA expression in THP-1 cells. a) The SLPI secretion in cell supernatants 
was analysed by ELISA at 20 h of incubation with isolates of L.crispatus, L.jensenii, or L.iners alone or in 
combination with E.coli at a total bacterial concentration of 108 per ml. b) SLPI mRNA expression in THP-1 
cells stimulated with L.iners 119 or E.coli alone or L.iners 119 and E.coli in combination for 1, 2 and 20 h at 
a total bacterial concentration of 108 per ml. Results are presented as fold change over constitutive 
expression. The bars represent SEM.  
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Correlations 
A negative correlation was obtained 
between SLPI and the TNF-α, IL-1α, IL-6, 
IL-8, or IL-18 levels (Table 3).  
UHeLa cells (III)
SLPI secretion
The presence of lactobacilli in E. coli
stimulated cells did not alter the reduction 
in SLPI secretion compared to that induced 
by E. coli alone, except for L. crispatus
(Table 2). L. crispatus gave rise to lower 
levels of SLPI than that induced by E. coli 
alone (p = 0.0007), and the SLPI secretion 
was further reduced, compared to 
constitutive levels by the combination L.
crispatus and E. coli (p < 0.0001).
Cytokines
Although the IL-6 and IL-8 responses 
induced by the different Lactobacillus
strains were weak in comparison to that 
induced by E. coli (Table 2), the presence 
of either L. iners 030, L. iners 119 or L
.jensenii 151, in combination with E. coli,
gave rise to significant synergy effects in 
the induction of IL-6, with an increase of 
28 – 36 % (p < 0.0001, p = 0.0116 and p = 
0.0165 respectively). The combination of 
either of the L. iners strains with E. coli
induced approximately three – fold higher 
levels of IL-8 (p < 0.0001) than E. coli did 
alone. The combinations of L. crispatus, L.
jensenii 003 or L. jensenii 151 with E. coli
roughly induced IL-8 1.5–2 times more 
than that induced by E. coli alone (p = 
0.0023, p = 0.001 and p = 0.0388 
respectively).  
Correlations 
Negative correlations were obtained 
between the levels of SLPI and IL-6 (r = - 
0,9472 and p = 0,0145) or IL-8 (r = 0,9862 
and p = 0.0019) in HeLa cells incubated 
with the various lactobacilli.   
Effects of exogenous administrated SLPI 
on the cytokine secretion in HeLa cells 
(III)
Since we had found a negative correlation 
between SLPI and the IL-6 or IL-8 levels 
induced by the Lactobacillus species, we 
proceeded to investigate if added 
recombinant SLPI (rhSLPI) could alter the 
secretion of these cytokines in HeLa cells. 
rhSLPI was added to HeLa cells prior to 
the incubation with E. coli. The IL-6 and 
IL-8 protein secretion was subsequently 
measured in cell supernatants by ELISA 
and IL-8 mRNA expression by RT-PCR 
(fig 16).
Both the IL-6 and IL-8 responses induced 
by E.coli were significantly down-
regulated at 20 h in cells pre-treated with 
rhSLPI (fig.16 a). Further analysis of the 
IL-8 mRNA expression showed that the 
reduction in the cytokine protein levels 
was reflected in the corresponding mRNA 
expression (fig.16 b). 
Expression of Toll-like receptors 
(TLRs), MD-2 and CD14 on HeLa cells 
(III).
The mRNA expression of TLR-2, -4, -5, 
MD2 and CD14 in un-stimulated HeLa 
cells was analysed by PCR, in order to 
evaluate the capacity of HeLa cells to 
respond to the MAMPs of lactobacilli and 
E. coli. There was no detection of TLR-2 
or MD-2 expression in the cells, and a low 
expression of TLR-4, TLR-5 and CD-14 
(11 %, 19% and 2 % respectively of posi-
tive control). 
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Fig. 15. The cytokine levels of a) TNF-α, b) IL-8, c) IL-6 and d) IL-
18 in THP-1 cells stimulated for 20 h with isolates of L.crispatus,
L.jensenii or L.iners alone or in combination with E.coli at a total 
bacterial concentration of 108 per ml. The cytokine levels in THP-1 
cell supernatants were analysed by ELISA. The bars represent SEM. 
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Table 3
Correlation between SLPI and cytokine levels in THP-1 cells supernatants stimulated  with L.iners, 
L.jensenii. L.gasseri, L.crispatus or E.coli alone or each of the Lactobacillus isolates in combination 
with E.coli.
Cytokine
TNF-α IL-8                   IL-1α IL-6                 IL-18 
Corr.coeff.*   r =  -0,8456         r = -0,7163           r = -0,6079          r = -0,5777       r = -0,5944
P-value          p =  0,0005***    p = 0,0088**       p = 0,036*  p = 0,0492*      p = 0,0415*
* Spearman Rank Correlation. 
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Fig. 16. Effects of added rhSLPI on IL-6 and IL-8 responses in HeLa cells stimulated with E.coli. a)  
IL-6 and IL-8 secretion in HeLa cells incubated for 20 h with E.coli at 108 bacteria per ml with or 
without rhSLPI 10 μg per ml and analysed by ELISA. b) IL-8 mRNA expression in HeLa cells 
incubated for 20 h with E.coli at 108 bacteria per ml with or without rhSLPI added at a concentration 
of 10 μg per ml.  The IL-8 mRNA expression level in HeLa cells are compared to control. The bars in 
each point represent SEM of triplicates 
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Absorbtion of SLPI 
To exclude the possibility that SLPI was 
absorbed to bacterial surfaces or degraded 
by bacterial proteases and, thereby, 
reducing the SLPI available for 
measurement by ELISA, L.iners 119 or 
E.coli was incubated with rhSLPI. No 
significant differences of the SLPI levels, 
as compared to the control, were obtained 
when L. iners 119 or E. coli at 109 bacteria 
per ml, were incubated with rhSLPI at 
concentrations of 20 or 4 ng per ml for 20 
hours (fig. 17).
6. DISCUSSION 
In these studies we have explored some 
commensal bacteria isolated from the 
lower FGT for their interaction with host 
cells regarding their regulation and 
induction of innate immune factors and an 
opportunistic species (P. bivia) for 
virulence properties. 
In the first paper (I) we investigated 
possible pathogenic characteristics of 
P.bivia, a gram negative obligate anaerobic 
rod, frequently isolated in and associated 
with BV, PID, intra-amniotic infection and 
PTB [44, 45].
BV is a disturbance in the normal vaginal 
microbiota defined by a loss of lactobacilli 
and overgrowth of anaerobic bacteria, 
increasing the risk for uterine infections 
[30, 160, 161]. However, the mechanisms 
by which opportunistic bacteria such as 
P.bivia may ascend to the upper genital 
tract and cause infection are less well 
studied. Epithelial cell invasion is a 
strategy for the establishment of infection 
used by several bacterial pathogens such as 
Neisseria gonorrhoeae, Chlamydia
trachomatis, and enteropathogenic species 
of Salmonella, Shigella, Campylobacter, 
Yersinia and E.coli [59, 103, 104, 162-
165]. Also, anaerobic Gram negative 
bacteria such as Prevotella intermedia,
Porphyromonas gingivalis, and Actino-
bacillus actinomycetemcomitans have been 
shown to invade human epithelial cells,  
and it has been suggested as a pathogenic 
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Fig. 17. Absorption experiment, simulating the cell assay procedure. L.iners or 
E.coli at 109 bacteria per ml was incubated with rhSLPI at 4 or 20 ng per ml in 
the absence of HeLa cells and incubated over night. The supernatants were 
analysed by ELISA. The bars in each point represent SEM of triplicates. 
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mechanism for a chronic infection with a 
slowly progressing inflammation and 
destruction of tissue  [105-108]. 
In paper (I), five strains of P.bivia were
tested for adherence, invasion and cytokine 
stimulation in human cervix epithelial cells 
(HeLa). The results demonstrated that 
P.bivia is capable to adhere to and invade 
HeLa cells in vitro. However, the invasion 
capacity varied strongly among the five 
isolates of P.bivia, where the number of 
intracellular bacteria differed more than 
100-fold (fig.1). This variation appeared 
not to be due to the adherence of bacteria 
to the epithelial cells, since all strains 
adhered to approximately the same extent. 
Rather, it indicated that some strains may 
be endowed with factors that promote 
internalization. To our knowledge, nothing 
is known about the expression of fimbriae 
or any other outer membrane factors of 
P.bivia that could mediate an attachment to 
the host cell surface and induce a 
subsequent internalization. Different types 
of fimbriae have previously been identified 
on the periodontal pathogen Prevotella
intermedia as examined by electron 
microscopy (EM) [157]. However, in our 
study, no visible evidence of fimbriae 
could be detected on the surface of the 
most invasive P.bivia strain (P47) by EM. 
Despite that we could not identify any 
adhesion structures on P47, the number of 
intracellular P47 per HeLa cell was close 
to that previously reported for the piliated 
N. gonorrhoeae [61], and the invasion 
efficiency of P47 (0.2 %) was in the same 
range of that reported for P.intermedia, N.
gonorrhoeae or group B streptococci (~ 
0.2 %- 0.4%) in epithelial cells [61, 105, 
166].
Both invasive C. trachomatis and N.
gonorrhoeae have been reported to induce 
a release of IL-1α, IL-6 and IL-8 in 
cervical cells, but only a piliated N.
gonorrhoeae induced IL-1α while neither 
the presence of pili nor invasiveness of N. 
gonorrhoeae was shown to be essential for 
the IL-6- or IL-8 responses [61, 63]. In our 
study, internalization of P. bivia but not the 
adherence capacity appeared to correlate to 
the secretion of IL-6 and IL-8, since none 
of the P. bivia strains except P47 was able 
to elicit detectable cytokine levels in the 
cells. In comparison with E.coli, however, 
the cytokine response to P47 was quite 
weak.
Increased levels of IL-1 and IL-8, in the 
lower genital tract have been associated 
with BV, whereas no significant difference 
in the IL-6 levels in cervico-vaginal fluids 
have been observed between healthy 
women and women with BV [125, 127, 
128, 167]. The weak induction of IL-6 
induced by P.bivia in HeLa cells in our 
study support the lack of a significant IL-6 
response clinically observed in BV [125, 
127, 128, 168, 169]. 
In summary, we demonstrated in this study 
that the opportunistic bacterium, P.bivia,
can invade human cervix epithelial cells in 
vitro and that this capacity varies widely 
between different isolates of P.bivia.
Furthermore, the results suggest that a 
strong intracellular invasion capacity could 
be a virulence factor for an ascending route 
of infection of the upper FGT by P.bivia.
An intracellular localization may be a 
defence mechanism by which P.bivia
could escape the hostile milieu that the 
cervical canal represents [170]. 
Hypothetically, the capacity to invade 
epithelial cells could also be a mechanism 
for P.bivia to enter into the amniotic cavity 
of pregnant women, giving rise to a 
subclinical infection. The very weak pro-
inflammatory cytokine response induced 
by the bacterium in cervix epithelial cells 
may represent another important property 
of P.bivia that may facilitate its spread and 
persistence in other areas. 
In paper (II) and (III) our aim was to 
explore the role of vaginal lactobacilli as 
possible regulators of innate immune 
factors such as SLPI and cytokines in 
cervix epithelial cells (III) and in 
monocytes (II).
Since SLPI is present in high 
concentrations in cervico-vaginal secretion 
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in women colonized by commensal 
lactobacilli but decreased in BV and STDs, 
together with our findings that L.iners
correlated with levels of SLPI [91, 171], 
we reasoned that lactobacilli may influence 
the regulation of constitutive and inducible 
innate immune factors such as SLPI and 
pro-inflammatory cytokines in host cells. 
L. iners, L. crispatus, L. gasseri, and L. 
jensenii, which have been reported in 
several studies as the four most pre-
dominant vaginal Lactobacillus species in 
the lower genital tract of normal healthy 
women of fertile age [47, 85, 95] [171] 
were analysed for their abilities to regulate 
SLPI and cytokine responses in THP-1(II) 
and HeLa cells (III). 
L.iners was the only one of the four tested 
lactobacilli spp. that gave rise to an up-
regulation of the SLPI secretion in THP-1 
cells. This effect was not observed in HeLa 
cells incubated at the same concentration 
of L.iners. The SLPI secretion in HeLa 
cells remained at a constitutive level, 
which was approximately 50 times higher 
than the constitutive level in THP-1 cells. 
However, high concentrations of L.iners
induced a down regulation of the SLPI 
levels in both cell types.
A large difference was observed between 
L.iners and L.crispatus in their induction 
of SLPI secretion irrespective of the 
bacterial concentration tested. While 
L.iners did not affect or up-regulate the 
SLPI secretion, all concentrations of 
L.crispatus gave rise to a considerable 
down-regulation of SLPI in both cells. 
Compared with L.crispatus and E.coli, a 
tenfold higher concentration of L.iners was 
needed to down-regulate the constitutive 
SLPI secretion in both HeLa and THP-1 
cells.
In the host cells there are both extracellular 
and intracellular pattern recognition 
receptors (PRRs) such as Toll like 
receptors (TLRs) and NOD-like receptors 
(NLR). PRRs may be expressed differently 
in HeLa cells and THP-1 cells, which may 
be one explanation to the differences in 
SLPI regulation observed in the cells. 
In addition, the difference in SLPI 
secretion in response to different bacterial 
species, or strains thereof, may reflect 
differences in the exposure of various 
conserved microbial associated molecular 
patterns (MAMPs) such as peptidoglycan, 
LTA and LPS by the bacteria. Various 
expression patterns of these molecular 
structures may lead to differently 
modulated host responses depending on 
which receptor or combination of receptors 
the bacteria bind to [172].  Furthermore, it 
is likely that more than one type of PRR is 
activated by the bacteria. This implies that 
microbes individually may tailor colla-
boration between different PRRs and hence 
the signalling response in the host cell 
[173]. The activation of intracellular 
signalling pathways by the bacteria may 
subsequently directly or indirectly affect 
the regulation of SLPI.
The negative correlation obtained between 
the levels of cytokines and SLPI in both 
HeLa and THP-1 cells stimulated with 
lactobacilli or E.coli alone or in 
combination suggests that cytokines may 
take part in a regulation of SLPI. The 
inverse correlation may reflect an 
“inflammatory state” in the cells, in which 
SLPI is directly or indirectly down-
regulated in response to high levels of 
microbes and/or by the cytokines which 
they may induce. This inverse relayion 
between SLPI and cytokines in our study 
are in line with the observations in vivo
where the SLPI levels are reported to be 
decreased and the cytokine levels elevated 
in vaginal fluids in women with STDs 
and/or BV [91, 125, 147]. 
In addition, exogenous administration of 
cytokines have been reported to influence 
the expression of SLPI in murine 
macrophages where SLPI mRNA was up-
regulated by IL-6 and IL-10 and down-
regulated by IFN-? [139, 161]. Since a 
high concentration of bacteria induced 
quite strong cytokine responses including 
IL-6, it could be an explanation for the up-
regulated mRNA levels observed in both 
THP-1 and HeLa cells in our study.
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An inverse relationship between SLPI and 
cytokines has been reported by several 
studies. Exogenously added rhSLPI was 
shown to down-regulate the TNF-?
secretion in LPS activated human 
monocytes/ macrophages [174], and 
reduced an inflammatory reaction in 
response to the deposition of IgG immune 
complexes in an acute lung injury model 
[175]. Based on several studies the 
evidence indicates that SLPI down 
regulates the activation of NF-kB [140, 
174-178]. In our study of the anti-
inflammatory effect of SLPI in HeLa cells, 
there was a significant down-regulation of 
both the IL-6 and IL-8 responses by the 
addition of rhSLPI to the cells prior to the 
exposure to E.coli. Thus, cervix epithelial 
cells behave similar to innate immune 
cells. 
There was no obvious correlation between 
the SLPI protein secretion and mRNA 
expression in THP-1 cells stimulated with 
L.iners. In HeLa cells, however, there was 
an inverse correlation between SLPI 
protein and mRNA levels. For example, at 
1 h of incubation, all tested concentrations 
of L.iners gave rise to an up-regulation of 
the mRNA expression above constitutive 
levels in THP-1 cells followed by a 
subsequent decrease at 2h and 20 h to a 
constitutive level or below. The up-
regulation of mRNA in THP-1 cells at 1 h 
may reflect the up-regulation of SLPI 
protein secretion seen at 20 h when 
stimulating the cells with L.iners at 107 or 
108 bacteria per ml. At the same time 
points however, there was an inverse 
correlation between the SLPI mRNA and 
protein levels by the incubation of L.iners
at 109 per ml. A similar discrepancy 
between mRNA and SLPI protein levels 
were obtained in the HeLa cells, where the 
reduced SLPI secretion observed at 20 h 
with 109 L.iners or E.coli 108 bacteria per 
ml were not reflected in the mRNA 
expression (fig 11). Both cell types seemed 
to have the ability to up-regulate SLPI 
mRNA in response to L.iners, albeit at 
different time points and at different 
concentrations of L.iners.
The contradicting results of high SLPI 
mRNA levels but reduced protein levels 
could not be explained by absorption of 
secreted SLPI to the bacteria, since 
incubation by the same concentration of 
bacteria with rhSLPI did not result in 
reduced SLPI levels. In this experiment, a 
degradation of SLPI by a direct role of 
secreted proteases from the various 
bacterial species could also be excluded. 
Furthermore, the binding of SLPI to 
proteases secreted by the cells could also 
be ruled out since the analysis of SLPI 
levels in cell supernatants by our 
immunoassay gave identical results when 
compared to results obtained by a SLPI kit 
tested for cross reactivity and interference 
with elastase, trypsin or chymotrypsin. 
The SLPI secretion may be regulated by an 
intracellular post-translational degradation 
mechanism similar to that of Helicobacter
pylori infected human gastric tumour cell 
lines in which an inverse relationship 
between the SLPI protein levels and its 
corresponding mRNA expression has been 
shown [179]. In their study the incubation 
with H.pylori resulted in decreased or 
unchanged SLPI protein levels but with a 
corresponding up-regulation of the SLPI 
mRNA levels. However, as the 
intracellular SLPI levels did correlate with 
secreted SLPI levels an intracellular post-
translational mechanism of the regulation 
of SLPI secretion was suggested.
All tested combinations of lactobacilli 
together with E.coli gave rise to synergy 
effects in the induction of cytokines in both 
THP-1 and HeLa cells. Positive synergy 
effects were obtained for the IL-8 and 
TNF-? production in THP-1 cells and for 
IL-6 and IL-8 in HeLa cells. Negative 
synergy effects were obtained for IL-6 and 
IL-18 in THP-1 cells (fig. 15 and table 2). 
Overall, the vaginal lactobacilli enhanced 
the IL-6 and IL-8 responses in HeLa cells, 
and the IL-8 and TNF-? response in the 
THP-1 cells. A possible explanation to the 
positive synergy effects in the cytokine 
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induction may be a simultaneous activation 
of different PRRs such as TLRs and/or 
NLRs.  In several studies, positive synergy 
effects in cytokine responses have been 
demonstrated by simultaneous activation 
of different TLRs as well as the activation 
of a combination of TLRs and NLRs by 
various bacterial cell-wall factors [180-
183]. The negative synergy effect seen in 
the IL-6 and IL-18 responses is not easily 
explained. There is one report on the 
down-regulation of the transcription of a 
number of pro-inflammatory mediators by 
the intestinal Lactobacillus, L.casei, in 
response to Shigella flexneri in cultured 
intestinal epithelial cells [184]. However in 
this study the expression of all cytokines 
and chemokines were down-regulated. 
In conclusion, our results indicate that 
vaginal Lactobacillus species may 
contribute to a regulation of the host innate 
immune defence by the modulation of 
SLPI and cytokine responses. L.iners
appeared to be the only species that 
consistently enhanced or did not change 
constitutive levels of SLPI whereas the 
opposite was true for L.crispatus.
SLPI was down-regulated in response to 
the combination of lactobacilli and E.coli
or by the exposure to high doses of either 
bacteria alone. However, much higher 
concentrations of L.iners than E.coli were 
required to initiate a decrease of the SLPI 
secretion in both cell types. 
It is possible that the down-regulation of 
SLPI secretion seen in THP-1 and HeLa 
cells is a general phenomenon in non-
sterile body areas in response to interaction 
with pathogens or at a threshold 
concentration of any bacteria,. also 
commensal lactobacilli. Our results 
indicate that the triggering factor for the 
downregulation of SLPI secretion may be 
associated with the induction of a 
proinflammatory response.
The presence of high SLPI levels in vivo
may indicate a genital tract mucosa 
homeostasis including a balanced 
colonization of certain commensal bacteria 
such as L.iners. 
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